Valuation: GENFIT

Market Cap 588M 675M 557M 506M 945M 64.69B 950M 6.63B 2.56B 32.87B 2.54B 2.48B 105B P/E 2026 *
30.3x
P/E 2027 * 67.1x
Enterprise Value 537M 617M 508M 462M 863M 59.07B 867M 6.06B 2.34B 30.02B 2.32B 2.27B 96.09B EV / Sales 2026 *
5.36x
EV / Sales 2027 * 4.1x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day+2.05%
Current month-16.50%
1 month-7.73%
3 months+26.62%
6 months+40.80%
Current year+127.65%
1 week 11.7
Extreme 11.7
12.96
1 month 11.7
Extreme 11.7
14.46
Current year 5.08
Extreme 5.075
14.86
1 year 3.01
Extreme 3.006
14.86
3 years 2.8
Extreme 2.8
14.86
5 years 2.74
Extreme 2.74
14.86
10 years 2.74
Extreme 2.74
33.76
Manager TitleAgeSince
Chief Executive Officer 58 15/09/2019
Director of Finance/CFO 52 21/04/2021
Chief Tech/Sci/R&D Officer - 26/11/2025
Director TitleAgeSince
Chairman 70 15/06/2017
Director/Board Member 54 14/09/1999
Director/Board Member 58 15/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
+2.05%0.00% - - 693M
+1.23%+1.87%-0.15%+9.57% 45.91B
+0.23%+4.72%+44.32%+27.27% 44.25B
+0.52%-3.15%+349.53%+520.09% 41.99B
+1.55%+3.41%+6.40%+76.45% 39.58B
+1.75%-1.53%+12.22%+41.11% 31.08B
-0.20%+5.49%+23.57%+119.72% 17.21B
-3.49%-8.49% - - 16.27B
+2.92%+8.40%+22.46%+38.87% 14.96B
-2.45%+2.41%-3.16%-35.16% 13.42B
Average +0.41%+1.55%+56.90%+99.74% 29.41B
Weighted average by Cap. +0.59%+0.70%+72.32%+120.61%

Financials

2026 *2027 *
Net sales 100M 115M 94.91M 86.24M 161M 11.03B 162M 1.13B 437M 5.6B 433M 423M 17.94B 127M 146M 120M 109M 204M 13.97B 205M 1.43B 554M 7.1B 548M 536M 22.72B
Net income 22.88M 26.27M 21.65M 19.67M 36.75M 2.52B 36.93M 258M 99.72M 1.28B 98.67M 96.48M 4.09B 9.07M 10.41M 8.58M 7.8M 14.56M 997M 14.64M 102M 39.52M 507M 39.1M 38.23M 1.62B
Net Debt -51.11M -58.68M -48.37M -43.95M -82.1M -5.62B -82.5M -576M -223M -2.86B -220M -216M -9.14B -67.56M -77.56M -63.94M -58.09M -109M -7.43B -109M -762M -294M -3.78B -291M -285M -12.09B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Date Price Change
17/09/26 €11.94 +2.05%
16/09/26 €11.70 -6.25%
15/09/26 €12.48 -3.70%
14/09/26 €12.96 -5.68%
11/09/26 €13.74 +15.08%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
11.76EUR
Average target price
18.10EUR
Spread / Average Target
+53.91%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!